Former President Joe Biden has recently been diagnosed with prostate cancer, with his office announcing that he has an aggressive form of the disease that has spread to his bones. Despite the seriousness of his condition, there are promising treatment options available that could potentially extend his life for several years.
Biden’s Gleason score, a measure of the severity of prostate cancer, is 9 out of 10, putting him in the highest risk category known as Gleason Grade Group 5. This score indicates that a significant portion of his prostate cells appear abnormal and suggests a fast-spreading cancer. According to oncologist Marc B. Garnick, Biden’s Gleason score indicates the most aggressive form of cancer.
Metastatic prostate cancer, like Biden’s, is challenging to treat as it has already spread beyond the prostate to other parts of the body, such as the bones. Peter Nelson, a specialist in precision oncology, notes that metastatic prostate cancer is typically incurable, making Biden’s situation very serious. The extent and location of the cancer’s spread will be crucial in determining the best course of treatment.
The recommended treatment for Biden’s cancer, known as metastatic hormone-sensitive prostate cancer, is likely to involve a combination of drugs that target testosterone production and activity. Testosterone plays a crucial role in fueling the growth of prostate cancer cells, and blocking its effects can help shrink the tumor and bone lesions. Drugs such as leuprolide and apalutamide may be prescribed to achieve this.
While the treatment is expected to be effective initially, it is not a cure, and the cancer may eventually become resistant to therapy. Side effects such as muscle loss, bone health deterioration, and metabolic changes are common with hormone therapy. However, advancements in treatment research have significantly improved survival rates for patients with metastatic prostate cancer.
In addition to hormone therapy, Biden’s doctors may conduct genetic testing on his tumor to identify any mutations that could guide specialized treatments. Some prostate cancers are genetically linked to other cancers, such as breast and ovarian cancer, through genes like BRCA1 and BRCA2. Understanding these genetic abnormalities can help tailor treatment approaches for better outcomes.
Overall, while the road ahead may be challenging, Joe Biden’s prognosis is more hopeful than it would have been in the past, thanks to advancements in cancer treatment. With a comprehensive treatment plan that includes hormone therapy and genetic testing, Biden’s medical team is working towards managing his cancer and prolonging his life. Prostate cancer is a prevalent form of cancer among older men, with the American Cancer Society estimating that there will be around 313,780 new cases and 35,770 deaths in the U.S. in 2025. It is not uncommon for men in their 60s to 80s to receive a prostate cancer diagnosis, as it affects one in eight men in the country.
Former Vice President Joe Biden, who is in his 70s, recently revealed that he has been diagnosed with prostate cancer. If his case is severe, he may be prescribed specific drugs such as poly (ADP-ribose) polymerase (PARP) inhibitors, which target the type of prostate cancer he has. Dr. Nelson, a cancer researcher, acknowledges that Biden has been a strong advocate for biomedical research and cancer initiatives, and notes the importance of continued investment in cancer research to develop better therapies and ultimately find cures.
In contrast, President Donald Trump, who succeeded Biden, has made cuts to funding for cancer research and reduced staff at the National Institutes of Health. Dr. Nelson emphasizes the need for sustained investment in biomedical research to make progress in treating advanced prostate cancer and finding cures. Despite advancements in extending men’s lives with prostate cancer, there is still a long way to go in finding effective treatments.
As the fight against cancer continues, it is crucial to prioritize funding for research and support initiatives that aim to improve outcomes for patients like Biden. By staying committed to advancing biomedical research, we can work towards a future where prostate cancer is no longer a life-threatening disease.
